15 Posts Not to Miss from the 3rd Day of ASCO 2025 - OncoDaily 15 Posts Not to Miss from the 3rd Day of ASCO 2025 / American Society of Clinical Oncology, Armando Orlandi, ASCO, ASCO 2025, ASCO 25, ATOMIC trial, cancer,

15 Posts Not to Miss from the 3rd Day of ASCO 2025
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social ‬

oncodaily.com/societies/as...

#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment - OncoDaily MATTERHORN trial at ASCO 2025: Durvalumab + FLOT improves event-free survival in resectable gastric cancer, signaling a new standard of care.

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment
@ascocancer.bsky.social

oncodaily.com/oncolibrary/...

#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology

What if immunotherapy could help cure certain GI cancers? The #MATTERHORNtrial is testing this—adding durvalumab before & after surgery more than doubled the number of patients with no visible cancer. FDA fast-track could be next. #ASCO25

🔗: meetings.asco.org/abstracts-presentations/...